Natera Inc (NTRA) - Product Pipeline Analysis, 2025 Update

Summary

Natera Inc (Natera) develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers a Renasight test to detect the genetic causes of kidney diseases, Horizon carrier screening test, Panorama non-invasive prenatal screening test, Empower hereditary cancer test, Vistara prenatal single gene screening test, Anora miscarriage test and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Natera Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


Natera Inc Company Overview
Natera Inc Company Snapshot
Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
Natera Inc – Pipeline Analysis Overview
Natera Inc - Key Facts
Natera Inc - Major Products and Services
Natera Inc Pipeline Products by Development Stage
Natera Inc Ongoing Clinical Trials by Trial Status
Natera Inc Pipeline Products Overview
Expanded NIPS Test
Expanded NIPS Test Product Overview
Panorama Non-Invasive Prenatal Expanded Test
Panorama Non-Invasive Prenatal Expanded Test Product Overview
Prospera Pancreas Transplant Rejection Test
Prospera Pancreas Transplant Rejection Test Product Overview
Reproductive Health Test
Reproductive Health Test Product Overview
Signatera - Breast Cancer
Signatera - Breast Cancer Product Overview
Signatera - Breast Cancer Clinical Trial
Signatera - Colorectal Cancer
Signatera - Colorectal Cancer Product Overview
Signatera - Colorectal Cancer Clinical Trial
Signatera - GI Tumors
Signatera - GI Tumors Product Overview
Signatera - GI Tumors Clinical Trial
Signatera - Lung Cancer (Opdivo)
Signatera - Lung Cancer (Opdivo) Product Overview
Signatera - Lung Cancer (Opdivo) Clinical Trial
Signatera - Metastatic Non-Small Cell Lung Cancer
Signatera - Metastatic Non-Small Cell Lung Cancer Product Overview
Signatera - Multiple Myeloma
Signatera - Multiple Myeloma Product Overview
Signatera - Non-Hodgkin's Lymphoma
Signatera - Non-Hodgkin's Lymphoma Product Overview
Signatera - Ovarian Cancer
Signatera - Ovarian Cancer Product Overview
Signatera - Ovarian Cancer Clinical Trial
Signatera - Pan-Cancer
Signatera - Pan-Cancer Product Overview
Signatera - Pancreatic Cancer
Signatera - Pancreatic Cancer Product Overview
Signatera - Prostate Cancer
Signatera - Prostate Cancer Product Overview
Signatera Companion Diagnostic - Tecentriq
Signatera Companion Diagnostic - Tecentriq Product Overview
Signatera MRD Test
Signatera MRD Test Product Overview
Signatera MRD Test Clinical Trial
Natera Inc - Key Competitors
Natera Inc - Key Employees
Natera Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Natera Inc, Recent Developments
Jun 04, 2025: Natera Announces Medicare Coverage for Signatera Genome
Jun 02, 2025: Signatera Genome Clinical Performance Highlighted at ASCO 2025
May 22, 2025: Natera to Present over 25 Signatera Studies at 2025 ASCO Annual Meeting
May 08, 2025: Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
May 07, 2025: Prospera Heart Test With DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
May 06, 2025: Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas
Apr 29, 2025: Prospective DEFINE-HT Study Demonstrates that Prospera Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
Apr 22, 2025: Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
Mar 25, 2025: DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
Mar 10, 2025: Natera Announces Enrollment of First Patients in the Heroes Clinical Trial in Metastatic HER2+ Breast Cancer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
Natera Inc Pipeline Products by Equipment Type
Natera Inc Pipeline Products by Indication
Natera Inc Ongoing Clinical Trials by Trial Status
Natera Inc, Key Facts
Natera Inc, Major Products and Services
Natera Inc Number of Pipeline Products by Development Stage
Natera Inc Pipeline Products Summary by Development Stage
Natera Inc Ongoing Clinical Trials by Trial Status
Natera Inc Ongoing Clinical Trials Summary
Expanded NIPS Test - Product Status
Expanded NIPS Test - Product Description
Panorama Non-Invasive Prenatal Expanded Test - Product Status
Panorama Non-Invasive Prenatal Expanded Test - Product Description
Prospera Pancreas Transplant Rejection Test - Product Status
Prospera Pancreas Transplant Rejection Test - Product Description
Reproductive Health Test - Product Status
Reproductive Health Test - Product Description
Signatera - Breast Cancer - Product Status
Signatera - Breast Cancer - Product Description
Signatera - Breast Cancer - A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Signatera - Breast Cancer - De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer in Long-term Persistent Response and Minimal Residual Disease Undetectable in Circulating Tumor DNA
Signatera - Breast Cancer - Elacestrant for Treating ER+/HER2- Breast Cancer Patients with ctDNA Relapse
Signatera - Breast Cancer - Personalized Detection of CtDNA for Patients with HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
Signatera - Breast Cancer - Pre-operative Phase II Trial for Breast Cancer with Nivolumab in Combination with Novel IO (BELLINI Trial)
Signatera - Breast Cancer - Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
Signatera - Colorectal Cancer - Product Status
Signatera - Colorectal Cancer - Product Description
Signatera - Colorectal Cancer - BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Signatera - Colorectal Cancer - Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II
Signatera - Colorectal Cancer - Clinical Experience of a Personalized and Tumor-informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients
Signatera - Colorectal Cancer - Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Signatera - Colorectal Cancer - Genetic Alterations and Clinical Record in Radically Resected Colorectal Cancer Revealed by Liquid Biopsy and Whole Exome Analysis
Signatera - Colorectal Cancer - Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
Signatera - GI Tumors - Product Status
Signatera - GI Tumors - Product Description
Signatera - GI Tumors - Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
Signatera - Lung Cancer (Opdivo) - Product Status
Signatera - Lung Cancer (Opdivo) - Product Description
Signatera - Lung Cancer (Opdivo) - Neoadjuvant Anti-PD-1 Drug Nivolumab Combined with Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
Signatera - Metastatic Non-Small Cell Lung Cancer - Product Status
Signatera - Metastatic Non-Small Cell Lung Cancer - Product Description
Signatera - Multiple Myeloma - Product Status
Signatera - Multiple Myeloma - Product Description
Signatera - Non-Hodgkin's Lymphoma - Product Status
Signatera - Non-Hodgkin's Lymphoma - Product Description
Signatera - Ovarian Cancer - Product Status
Signatera - Ovarian Cancer - Product Description
Signatera - Ovarian Cancer - Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Signatera - Pan-Cancer - Product Status
Signatera - Pan-Cancer - Product Description
Signatera - Pancreatic Cancer - Product Status
Signatera - Pancreatic Cancer - Product Description
Signatera - Prostate Cancer - Product Status
Signatera - Prostate Cancer - Product Description
Signatera Companion Diagnostic - Tecentriq - Product Status
Signatera Companion Diagnostic - Tecentriq - Product Description
Signatera MRD Test - Product Status
Signatera MRD Test - Product Description
Signatera MRD Test - A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
Signatera MRD Test - MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Natera Inc, Key Employees
Natera Inc, Other Locations
Natera Inc, Subsidiaries
Glossary
List of Figures
Natera Inc Pipeline Products by Equipment Type
Natera Inc Pipeline Products by Development Stage
Natera Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings